HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Twinlab

This article was originally published in The Tan Sheet

Executive Summary

Securities class actions filed against supplement firm and its officers in Islip, N.Y. federal court on behalf of purchasers of Twinlab stock between April 27, 1999 and Nov. 15, 2000. The lawsuits generally allege defendants issued materially false and misleading financial statements and misrepresented sales growth potential, particularly for herbals. The complaints also assert the firm overstated its physical inventory, and that Twinlab stock was artificially inflated as a result of these disclosure violations. On Nov. 15, Twinlab announced product returns from "major customers" and "inventory reduction" in the herbals and sport nutritional markets forced it to lower FY 2000 projections. The company's 10-Q filing with SEC had been delayed due to inventory discrepancies (1"The Tan Sheet" Nov. 20, p. 5)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel